Dear Reader,
It's a bold new recommendation from one of the boldest men to ever rule Wall Street:
"If you have $1,000 to invest today, move it into this stock now."
Artificial Intelligence stocks have minted over 600,000 new millionaires.
But now, American investors have been left to wonder: "What should I put my money into next?"
50-year Wall Street veteran Marc Chaikin just stepped forward with his answer – and his new #1 free stock recommendation. (See the name and ticker here, 100% free.)
And if you're following the mainstream financial media right now, I can almost guarantee his new prediction will surprise you.
"I don't believe the NEXT wave of massive stock winners will come from biotech, cryptos, or quantum computing," Marc says in his latest on-camera interview. "And for the biggest potential gains, forget about Nvidia and the rest of the Magnificent Seven."
Marc invented the Wall Street indicator that tracks the billions of dollars flowing through the U.S. stock market, every single day.
And he recently used it to zero in on a group of breakthrough companies he says are "hiding in plain sight..."
That could soon usher in massive potential profits for those who understand what's happening... and the exact stocks to buy now.
He tells the whole story in a shocking new interview, where he even shares the name and ticker of one of those "hidden" breakthrough stocks he says to buy now.
You can watch it for free here.
The last time Marc sat for an interview like this, over 11 million people tuned into watch.
And a stock he gave away, live on-camera, went on to soar 100%.
Regards,
Vic Lederman
Publisher, Chaikin Analytics
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Written by Chris Markoch. Published 10/8/2025.
Key Points
- Pfizer has rebounded on news of its participation with the TrumpRx platform, but questions remain about margins and the impact of its new pricing agreements.
- AbbVie offers stronger earnings growth potential, a deep late-stage pipeline, and smart onshoring moves to support future demand.
- Johnson & Johnson is emerging from legal headwinds with a leaner business model, attractive valuation, and a long dividend growth streak.
Pfizer Inc. (NYSE: PFE) jumped after becoming the first drug manufacturer to sign on to the TrumpRx platform. PFE is up nearly 14% since its close of roughly $23.61 on Sept. 25.
This is welcome news for long-term holders who endured a sharp decline after the vaccine-driven surge in 2021. PFE trades at an attractive multiple of about 9x forward earnings and remains a steady dividend payer with a yield of 6.4%.
Final Notice: 2025's Wealth Window Is About to Open (Ad)
The top small-cap signals for 2025 are already flashing — and once these moves begin, the entry window closes fast. Our free Wealth Building Report shows the signal pattern driving early momentum, the triggers to watch, and how to spot fast-moving setups before they accelerate.
Get your free Wealth Building Report before the 2025 window closesThat said, the details matter. Investors should seek answers to several questions — the most important being which drugs will be included. Pfizer will likely exempt its premium drugs, and with good reason: the program could boost volume but at lower prices that would pressure margins.
Meanwhile, the bull case for Pfizer centers on its pipeline of more than 100 drug candidates, many of which position the company in customizable medicine. That long-term potential may be a stronger reason to hold PFE. Still, two other medical stocks may be more suitable alternatives for some investors.
AbbVie’s Onshoring Strategy Aligns With U.S. Policy Goals
As of this writing, AbbVie Inc. (NYSE: ABBV) is not part of the TrumpRx platform. That doesn't mean it isn't taking steps to limit potential tariff exposure. The company has announced plans to onshore some manufacturing capacity in the United States — a key element of the administration's effort to tighten U.S. supply chains for critical industries.
In late September, AbbVie said it would launch its recently approved ovarian cancer drug, Elahere, in the United Kingdom at a list price matching the U.S. price. That aligns with the administration's call for drugmakers to offer the U.S. a "most‑favored‑nation" pricing approach.
Even before that announcement, at least two analysts had set a $251 price target on ABBV, roughly a 10% premium to its Oct. 6 price. Moreover, analysts are forecasting more than 13% earnings growth over the next 12 months, suggesting some price targets could be conservative.
Over the past five years, ABBV has returned over 225% total return, supported by steady earnings growth and a dividend yield of 2.87%. That performance highlights the strength of AbbVie's core franchises and its ability to balance income with innovation. The company also maintains a deep development pipeline, with more than 50 drug candidates in late-stage clinical trials.
Johnson & Johnson’s Streamlined Focus Strengthens Its Pharma Edge
Johnson & Johnson (NYSE: JNJ) offers a different way to play the pharmaceutical sector. J&J spun off its consumer-products business in 2023, leaving a streamlined company with three divisions, including a pharmaceuticals segment that develops drugs across immunology, oncology, neuroscience and infectious diseases.
Over the last five years, JNJ has produced a total return of more than 46%, much of which occurred in the past 12 months. The company is now moving past its long-running talc liability litigation, which had deterred many investors. The question is whether the recent gains represent a completed catch-up trade or if upside remains.
From a valuation standpoint, JNJ looks reasonable. Trading at roughly 17x earnings, the stock is below its historical average. Analysts have been raising their price targets ahead of the company's Oct. 14 earnings report, indicating renewed confidence. With a dividend yield of 2.76% and a 64-year record of consecutive increases, JNJ offers a mix of value, reliability and steady income.
This email is a sponsored email from Chaikin Analytics, a third-party advertiser of DividendStocks.com and MarketBeat.
This ad is sent on behalf of Chaikin Analytics, 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. If you would like to optout from receiving offers from Chaikin Analytics please click here.
If you need help with your account, don't hesitate to contact MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103. United States of America..